摘要
目的探讨趋化因子受体3（CXCR3）及趋化因子配体10（CXCL10）在乳腺癌中的表达及临床意义。方法采用免疫组织化学SP法及二步法对60例乳腺癌组织、20例乳腺纤维瘤组织及20例乳腺腺病组织分别进行CXCR3、CXCL10检测。结果乳腺癌中CXCR3（40／60，66．7％）、CXCL10（45／60，75％）的表达高于乳腺腺病[CXCR3（8／20，40％）X^2=4．44，P=0．035；CXCL10（10／20，50％）x。=4．36，P=0．037）]，乳腺癌中CXCR3的表达与有无腋窝淋巴结转移、临床分期、HER-2的表达有关（X^2=4．15，P=0．042；X^2=7．74，P：0．021；X^2=4．27，P=0．039），且CXCR3的表达强度与腋窝淋巴结转移数及临床分期目呈正相关（-=0．375，P=0．003；t=0．451，P=0．000）。结论CXCR3可能与乳腺癌的进展及早期转移有关，CXCR3可能作为乳腺癌的一个预后指标。
Objective To investigate the expression and clinical significance of CXCR3/CXCL10 in human cancer. Methods CXCR3 and CXCL10 were detected in 60 paraffinic tissues of patients with primary breast cancer, 20 of mammary fibroma and 20 of mastopathy by immunohistochemistry S-P method and two stage method. Results The expression of CXCR3 （40/60,66. 7% ） and CXCL10 （45/60,75%） in breast cancer was higher than that in mastopathy [ CXCR3 （8/20,40%） X^2 = 4.44, P = 0. 035 ; CXCL10 （10/20,50%）X^2 =4. 36, P =0. 037）]. The expression of CXCR3 was related to status of axillary lymph node metastasis, clinical stage and the expression of HER-2 （ X^2 = 4. 15, P = 0. 042 ; X^2 = 7. 74, P = 0. 021 ;X^2 = 4. 27, P = 0. 039）. The expression of CXCR3 had positive relationship to the number axillary lymph node metastasis（ rs = 0. 375, P = 0. 003）, clinical stage （ ri = 0. 451, P = 0. 000）. Conclusions CXCR3 may be related to the progression and metastasis of breast cancer, and it may be used as a marker of breast cancer prognosis.
出处
《中国医师杂志》
CAS
2011年第10期1305-1308,共4页
Journal of Chinese Physician
基金
国家自然基金资助项目（20972046）
